Middle East & Africa Parkinson’s Disease Treatment Market Size & Outlook

The parkinson’s disease treatment market in Middle East & Africa is expected to reach a projected revenue of US$ 316.9 million by 2030. A compound annual growth rate of 2.5% is expected of Middle East & Africa parkinson’s disease treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$277.3
Forecast, 2030 (US$M)
$316.9
CAGR, 2025 - 2030
2.5%
Report Coverage
Middle East & Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa parkinson’s disease treatment market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

MEA parkinson’s disease treatment market highlights

  • The MEA parkinson’s disease treatment market generated a revenue of USD 277.3 million in 2024.
  • The market is expected to grow at a CAGR of 2.5% from 2025 to 2030.
  • In terms of segment, carbidopa-levodopa was the largest revenue generating drug class in 2024.
  • Carbidopa-Levodopa is the most lucrative drug class segment registering the fastest growth during the forecast period.
  • Country-wise, Kuwait is expected to register the highest CAGR from 2025 to 2030.


MEA data book summary

Market revenue in 2024USD 277.3 million
Market revenue in 2030USD 316.9 million
Growth rate2.5% (CAGR from 2025 to 2030)
Largest segmentCarbidopa-levodopa
Fastest growing segmentCarbidopa-Levodopa
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCarbidopa-Levodopa, Dopamine Agonist, MAO-B Inhibitors, COMT inhibitors, Anticholinergics
Key market players worldwideNovartis AG ADR, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, GSK PLC, AbbVie Inc, H. Lundbeck AS Class A, Supernus Pharmaceuticals Inc, Amneal Pharmaceuticals Inc Ordinary Shares - Class A, Cerevel Therapeutics Holdings Inc Ordinary Shares


Other key industry trends

  • In terms of revenue, MEA region accounted for 4.9% of the global parkinson’s disease treatment market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 1,761.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Parkinson’s Disease Treatment Market Companies

Name Profile # Employees HQ Website
Amneal Pharmaceuticals Inc Ordinary Shares - Class A View profile 7700 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, United States, 08807 https://www.amneal.com
Cerevel Therapeutics Holdings Inc Ordinary Shares View profile 355 222 Jacobs Street, Suite 200, Cambridge, MA, United States, 02141 https://www.cerevel.com
Supernus Pharmaceuticals Inc View profile 652 9715 Key West Avenue, Rockville, MD, United States, 20850 https://www.supernus.com
H. Lundbeck AS Class A View profile 5700 Ottiliavej 9, Valby, Denmark, 2500 https://www.lundbeck.com
GSK PLC View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
AbbVie Inc View profile 50000 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 http://www.abbvieinvestor.com
Teva Pharmaceutical Industries Ltd View profile 37851 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 https://www.tevapharm.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

Middle East & Africa parkinson’s disease treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to parkinson’s disease treatment market will help companies and investors design strategic landscapes.


Carbidopa-levodopa was the largest segment with a revenue share of 25.82% in 2024. Horizon Databook has segmented the Middle East & Africa parkinson’s disease treatment market based on carbidopa-levodopa, dopamine agonist, mao-b inhibitors, comt inhibitors, anticholinergics covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Middle East & Africa parkinson’s disease treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa parkinson’s disease treatment market databook

  • Our clientele includes a mix of parkinson’s disease treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa parkinson’s disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa parkinson’s disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA parkinsons disease treatment market size, by country, 2018-2030 (US$M)

Middle East & Africa Parkinson’s Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)

MEA parkinsons disease treatment market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online